Linscomb & Williams, Inc. Biogen Inc. Transaction History

Linscomb & Williams, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 06, 2019	SELL	$219.29 - $241.72 $405,905 - $447,423	-1,851 Closed	0 $0
Q1 2019 May 09, 2019	BUY	$216.71 - $338.96 $48,543 - $75,927	224 Added 13.77%	1,851 $438,000
Q4 2018 Feb 08, 2019	SELL	$278.5 - $352.75 $50,408 - $63,847	-181 Reduced 10.01%	1,627 $490,000
Q3 2018 Nov 08, 2018	BUY	$293.51 - $383.83 $29,938 - $39,150	102 Added 5.98%	1,808 $639,000
Q2 2018 Aug 07, 2018	BUY	$257.52 - $306.91 $62,062 - $73,965	241 Added 16.45%	1,706 $495,000
Q1 2018 May 04, 2018	SELL	$260.13 - $367.91 $4,162 - $5,886	-16 Reduced 1.08%	1,465 $401,000
Q4 2017 Feb 02, 2018	BUY	$307.64 - $344.58 $54,144 - $60,646	176 Added 13.49%	1,481 $472,000
Q3 2017 Oct 27, 2017	BUY	$281.15 - $329.69 $366,900 - $430,245	1,305	1,305 $409,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $23B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Linscomb & Williams, Inc., based on Form 13F filings with the SEC.

Stay updated on Linscomb & Williams, Inc. with notifications on news.